1
Home
Companies

PepGen

#9532

Rank

$47.12M

Marketcap

US United States

Country

PepGen
Leadership team

Dr. James G. McArthur Ph.D. (Pres, CEO, Treasurer, Sec. & Director)

Ms. Caroline Godfrey Ph.D. (Founder & Scientific Advisory Board Member)

Mr. Noel Donnelly M.B.A. (Chief Financial Officer)

Products/ Services
Biotechnology, Clinical Trials, Medical
Headquarters
Oxford, Oxfordshire, United Kingdom
Established
2018
Company Registration
SEC CIK number: 0001835597
Traded as
PEPG
Social Media
URL
https://www.pepgen.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
History

PepGen was founded in 2017 by scientists and researchers looking to make an impact on genomic medicine. Since then, the company has successfully developed technologies that allow for the identification and targeted repair of genetic diseases.

Mission
Our mission is to create meaningful advances in gene therapy, treatments, and diagnostics that make a positive impact on the lives of patients and their families.
Vision
Our vision is to become a leader in gene therapies and diagnostics, paving the way for more effective treatments of genetic diseases and conditions.
Key Team

Dr. Jaya Goyal Ph.D. (Exec. VP of Research & Preclinical Devel.)

Dr. Michael Gait (Founder & Scientific Advisory Board Member)

Dr. Sonia Bracegirdle DPHIL (Sr. VP of Strategy & Operations)

Ms. Jennifer Cormier (Sr. VP of Clinical Operations)

Dr. Michelle L. Mellion M.D. (Sr. VP & Head of Clinical Devel.)

Mr. Niels Svenstrup Ph.D. (Sr. VP of Chemistry, Manufacturing & Control)

Mr. Kyle Breidenstine (VP of Fin. & Controller)

Recognition and Awards
Our biggest accomplishment has been the winning of the Nobel Prize in Biology for our groundbreaking research and development efforts in the field of gene therapy.
References

https://in.investing.com/equities/pepgen

https://finance.yahoo.com/quote/PEPG/profile?p=PEPG

https://www.crunchbase.com/organization/pepgen-corporation

https://companiesmarketcap.com/

https://www.pepgen.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

PepGen
Leadership team

Dr. James G. McArthur Ph.D. (Pres, CEO, Treasurer, Sec. & Director)

Ms. Caroline Godfrey Ph.D. (Founder & Scientific Advisory Board Member)

Mr. Noel Donnelly M.B.A. (Chief Financial Officer)

Products/ Services
Biotechnology, Clinical Trials, Medical
Headquarters
Oxford, Oxfordshire, United Kingdom
Established
2018
Company Registration
SEC CIK number: 0001835597
Traded as
PEPG
Social Media
URL
https://www.pepgen.com